Doug Ingram

New Capabilities

Defending Elevidys against safety questions and new competition

Regenxbio's RGX-202 met the main goal of its AFFINITY DUCHENNE trial in May 2026. In 93% of treated boys with usable biopsies, muscle made microdystrophin, a shortened form of the missing protein, at more than 10% of normal levels by week 12. The company finished dosing a confirmatory study and plans to file for FDA approval in the third quarter of 2026.

Updated Nov 1